Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)
(Not for submission under 57 Of R 1.33)

Application Number		10724397			
Filing Date		2003-12-01			
First Named Inventor	Goldenberg				
Art Unit		1618			
Examiner Name	Jagad	Jagadishwar Rao Samala			
Attornov Docket Number		220687			

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>				Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1										
If you wisl	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		_
			U.S.P	ATENT	APPLK	CATION PUBL	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation Name of Patentee or Applicant Releva		Columns,Line int Passages o s Appear				
	1								4		
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button			
				FOREIG	GN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or  v	Pages,Column where Relevan Passages or R Figures Appea	t elevant	Ι.
	1										
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	I lease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		_
Examiner Cite Initials* Cite Initials* Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							item	T			

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10724397
Filing Date		2003-12-01
First Named Inventor Golde		nberg
Art Unit		1618
Examiner Name	Jagadishwar Rao Samala	
Attorney Docket Number		330687

Date Considered

BEHR, TMOMAS, et al., "High-Lenes Cenegy Transfer (ELT) a versus Low-LET B Emillers in Radiominumentherapy of a first furnors. Thereprese Effective and Does having Toucher (ELT) a versus Low-LET B Emillers in Radiominumentherapy of an a Human Colone Cannor Model **Cannor Research (9, 2035-2643, June 1, 1990, XP-20068228)   GOVINDAN, SERENGULAMY, et al., "SOVItisum-Labeled Complementain/Detemmenting-Region-Called Monoclonal Androdes for Radiominum-otherapy." Resideableigh and Animal Bloodstitution Studies' Biocospugate Chem., vol. 9, No. 6, 1998, 773-782 XP-200682236   CASEY, J. L. et al., "Chestipne of yifistum 0.5 behalled ship-tumor artiblodes with antibodes reased against the 12N4 DOTA Macropole* British Journal of Cannor (1998) 78(10), 1307-1312 XP-200696694   ROWILINSON-BUSZ, GAIL, et al., "SOVI-Labeled Antibody Upbale by Haman Tumor Xenografis and The Effect of Systemic Administration of DDTA* flat. A readion Cheology Block Phys., Vol. 28, No. 5, pp. 1257-1265, 1994   VA-000696694	ii you mon to	FYAMINER SIGNATURE	
1 Solid Tumoss: Therapeatic Efficacy and Dose-limiting Toolsky of 2188-versus 901 stabled CO117-A Fab Tragments in a Human Colonic Core Model? Cancer Research50, 2055-2643, June 1, 1996, XP-000982282  COVINDAN, SERENGULAM V. et al. "Old Yorkins-Labeled Correspondentarly-Determining-Region-Caralled Monoclonal Authories for Radioimmunotherapy: Radioiabeling and Animal Biodistitution Shutles' Biocorpugate Chem., vol. 9, No. 6, 1988, 773-782 XP-000998220  CASEY, J. L., et al. "Clearance of ytmum-60-labeled anti-burour antibodies with antibodies raised against the 12N4 DOTA Macrocycle" British Journal of Cancer (1998) 78(10), 1307-1312 XP-000986994	ľ	Systemic Administration of EDTA* Int. J. Radiation Choology Biol. Phys., Vol. 28, No. 5, pp. 1257-1265, 1994 XP-000986989	
Suid Tumors: Therapeutic Efficacy and Dose-Brillian Toolsky of 2158-versus 901-stabled CO17-1.4 Fab Fragments in a Human Coloric Come Model Towns Descended 50, 255-543, June 1, 1969, 745-00062262  GOVINDAN, SERENGULAM V., et al., "901/thisum-tabeled Complementarity-Determining-Region-Grafted Monodonal Anthodos for Radiominus/otherapy: Radiothering and Animal Biodestifusion Studies" Biocorpugate Chem., vol. 9, No. 6, 1968, 773-92 W-900662268  CASEY, J. L., et al., "Citerannoe of yithrum-90-sibeleind and-tumour antibodies with antibodies rased against the 12744		ROWLINSON-BUSZ, GAIL, et al., "90Y-Labeled Antibody Uotake by Human Tumor Xenografis and The Effect of	
Solid Tumors: Therapeutic Efficacy and Dose-limiting Toology of 2158 versus 901 slabeed CO17-1A fab Fragments in a Human Colonic Cancer Model **Cancer Research59, 2535-2643, June 1, 1999, XP-200902242 Fab Colonic Cancer Model **Cancer Research59, 2535-2643, June 1, 1999, XP-200902242 Fab Colonic Cancer Model **Cancer Solid Soli	3		
1 Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi-versus 90Y-labeled CO17-1A Fab' Fragments	2	Antibodies for Radioimmunotherapy: Radiolabeling and Animal Biodistribution Studies" Bioconjugate Chem., vol. 9,	
	1	Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi-versus 90Y-labeled CO17-1A Fab' Fragments	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10724397		
	Filing Date		2003-12-01		
	First Named Inventor	Golde	enberg		
Art Unit			1618		
	Examiner Name	Jagao	fishwar Rao Samala		
Attorney Docket Number			330687		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.98 to make the	appropriate selection(s):
---------------	--------------	------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Richard A. Nakashima/	Date (YYYY-MM-DD)	2007-01-03
Name/Brint	Diebard A Makachima	Desistration Number	42 023

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operament of Commence, P. O. Box 1450, Alexandris, V.S. 2231-1450. D. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VAZ 2321-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral purpuses for which the information is used by the U.S. Patient and Trademan Colline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested region of the patient of the patient application of the patient application of the patient activities, which may result in farministion of proceedings or 4 anahoroment of the application of the patients of the pa

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.